UnknownNot Applicable

Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19

France300 participantsStarted 2020-04-21

Plain-language summary

The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to report the results of the ECMO management of the most severe forms of COVID-19 through the first French ECMO registry.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All COVID-19 patients, adults or children, * Tested positive by RT-PCR for SARS-CoV2 (nasopharyngeal swabs, sputum, endotracheal aspiration, bronchoalveolar lavage or stool sample) and / or with a diagnosis made on chest CT findings, * Supported by venovenous or venoarterial ECMO Exclusion Criteria: * Temporary legally protected Adults over a set period or waiting for protection supervision, guardianship * Patients or proxies who express their opposition to study participation

What they're measuring

Hospital mortality

Timeframe: up to 90 days

Trial details

NCT IDNCT04397588

SponsorRennes University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-10-21

Contact for this trial

Cécile Ferragu

0299282555 cecile.ferragu@chu-rennes.fr

View on ClinicalTrials.gov More ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2 trials